Comparative Pharmacology
Head-to-head clinical analysis: BUTAZOLIDIN versus NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTAZOLIDIN versus NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE.
BUTAZOLIDIN vs NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Diphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms and inducing sedation via central H1 blockade.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
One tablet (naproxen sodium 220 mg / diphenhydramine hydrochloride 25 mg) orally every 8 hours as needed, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
Naproxen: 12-17 hours (mean ~14 hours); clinically, allows twice-daily dosing for sustained anti-inflammatory effect. Diphenhydramine: 4-10 hours (mean ~7 hours); shorter half-life supports sedative effect for sleep induction.
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Naproxen: renal excretion of naproxen and its metabolites (95% as unchanged drug and conjugated metabolites, primarily 6-O-desmethylnaproxen). Diphenhydramine: renal excretion of unchanged drug and metabolites (primarily as diphenylmethoxyacetic acid); approximately 50-60% eliminated in urine as unchanged drug and metabolites, with a small fraction in feces.
Category C
Category D/X
NSAID
NSAID